Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05061420 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) | terminated | Phase 2 | 59 | SanofiINDUSTRY | 11 | Sep 22, 2025 | clinicaltrials |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | terminated | Phase 2 | 37 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 |
| Sep 19, 2025 |
| clinicaltrials |
| NCT03446040 | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | terminated | Phase 1 / Phase 2 | 92 | Bristol-Myers SquibbINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT04191382 | Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer(AMEERA-4) | terminated | Phase 2 | 105 | SanofiINDUSTRY | 9 | Sep 18, 2025 | clinicaltrials |
| NCT04023331 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | terminated | Phase 1 / Phase 2 | 21 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04249622 | Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer | terminated | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT06175221 | Autologous TLPO Vaccine Basket | terminated | Phase 2 | 63 | Elios Therapeutics, LLCINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | terminated | Phase 2 | 180 | NuCana plcOTHER | 6 | Sep 12, 2025 | clinicaltrials |
| NCT06226766 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | terminated | Phase 1 / Phase 2 | 11 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07166367 | Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer | terminated | Phase 2 | 3 | National Cancer Centre, SingaporeOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03347617 | Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma | terminated | Phase 2 | 52 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC | terminated | Phase 1 / Phase 2 | 10 | CytoDyn, Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia(ISAKIDS) | terminated | Phase 2 | 67 | SanofiINDUSTRY | 16 | Sep 9, 2025 | clinicaltrials |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)(5) | terminated | Phase 2 | 10 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04887831 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab(PRESERVE3) | terminated | Phase 2 | 92 | G1 Therapeutics, Inc.INDUSTRY | 5 | Sep 8, 2025 | clinicaltrials |
| NCT05662670 | A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 14 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03564678 | Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05222269 | [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients | terminated | Phase 2 | 1 | Pentixapharm AGINDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 6 | PfizerINDUSTRY | 3 | Sep 5, 2025 | clinicaltrials |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 10 | STCube, Inc.INDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT05577715 | A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 4, 2025 | clinicaltrials |
| NCT00766142 | Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer(COCHISE) | terminated | Phase 2 | 18 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | terminated | Phase 2 | 17 | University of Alabama at BirminghamOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05245071 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA(CARMEN-LC06) | terminated | Phase 2 | 22 | SanofiINDUSTRY | 7 | Aug 29, 2025 | clinicaltrials |
| NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | terminated | Phase 2 | 255 | Seagen Inc.INDUSTRY | 6 | Aug 28, 2025 | clinicaltrials |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03376477 | Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission | terminated | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients(PEMAZA) | terminated | Phase 2 | 26 | Technische Universität DresdenOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT00015847 | Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | terminated | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05208177 | A Study of SHR-1802 in Patients With Advanced Solid Tumor | terminated | Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT05109442 | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | terminated | Phase 1 / Phase 2 | 112 | Affimed GmbHINDUSTRY | 5 | Aug 20, 2025 | clinicaltrials |
| NCT05883449 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL(LuminICE-203) | terminated | Phase 2 | 25 | Affimed GmbHINDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT02807597 | Real-time Intraoperative Breast Cancer Visualization for Margin Assessment | terminated | Phase 1 / Phase 2 | 9 | Samuel AchilefuOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT04936230 | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06321068 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer | terminated | Phase 2 / Phase 3 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | terminated | Phase 2 | 15 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | terminated | Phase 1 / Phase 2 | 6 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | terminated | Phase 2 / Phase 3 | 11 | University Health Network, TorontoOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | terminated | Phase 1 / Phase 2 | 6 | Inge Marie SvaneOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | terminated | Phase 2 | 6 | University of WashingtonOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03018288 | Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) | terminated | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2025 | clinicaltrials |
| NCT04433182 | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 37 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 243 | GlaxoSmithKlineINDUSTRY | 12 | Aug 8, 2025 | clinicaltrials |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 7 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 22, 2025source: clinicaltrials